Objective: Colchicine is a tricyclic alkaloid drugand it’s been clinically used for a long time because ofits anti-inflammatory effects. While colchicine has beensafely used in oral applications, it’s been demonstratedthat colchicine is toxic at higher concentrations. So,the mechanism of effects of low dose colchicine hasbeen studied in cancer related researches. Matrixmetalloproteinase-2 (MMP-2) is a member of matrixmetalloproteinase enzyme family and it’s beendemonstrated that MMP-2 expression is increased incancer and it causes a metastasis of cancer cells throughdegradation of extracellular matrix. Because of thisimportant effect of MMPs, the studies related to developMMP inhibitor compounds have great importance incancer investigations. At present study, it’s aimed toinvestigate the effects of colchicine on cell cycle arrestand MMP-2 mRNA expression in MCF-7 human breastcancer cells.Methods: In the study, MCF-7 human breastadenocarcinoma cells were purchased from ATCC.Cells were treated with 0.1, 10 ve 100 μg/mlcolchicine and cell viability was determined via MTTassay. The effect of colchicine on cell cycle arrest wasdetermined by Muse Cell Analyzer and the percent ofcell populations at G0/G1, S and G2/M cycles wereidentified. The effect of colchicine on MMP-2 mRNAexpression has been performed by real-time PCR (qRTPCR) analysis.Results: Colchicine has significantly inhibitedcell viability at 10 and 100 μg/ml concentrations. It’sbeen also demonstrated that colchicine has induceda cell cycle arrest at G2/M phase and downregulatedMMP-2 mRNA expression of MCF-7 cells in all treatedconcentration (p<0.0001).Conclusion: The results of this study illustratedthat colchicine may be a candidate anticancercompound for breast cancer studies and further studiesare required to identify the underlying mechanism ofeffects.
|
